Bharat Biotech launches oral cholera vaccine
Bharat Biotech International Ltd has launched Hillchol (BBV131), a novel single-strain oral cholera vaccine developed under license from Hilleman Laboratories.
Bharat Biotech International Ltd on Tuesday announced the launch of Hillchol, a novel single-strain oral cholera vaccine. A press release from the vaccine maker said Hillchol (BBV131) was developed by Bharat Biotech under license from Hilleman Laboratories (funded by Merck USA and Wellcome Trust) to combat Cholera.
Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control. Globally, there is a shortage of OCVs as there is only one manufacturer. BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, it further said.
A multi-stage, clinical evolution process, culminating in a phase 3 study confirmed the vaccine safety, immunogenicity, and non-inferiority to existing OCVs, establishing its potential for white spirit, and public health use. The vaccine, a single dose capsule, is administered orally on days 0 and 14 and is suitable for individuals older than one year.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
IRCTC Dividend 2024: Railway PSU announces 200% interim dividend - Check record date and other details
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
03:09 PM IST